Invest in 5,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany. more
Time Frame | BNTX | Sector | S&P500 |
---|---|---|---|
1-Week Return | 0.46% | 0.71% | 1.64% |
1-Month Return | -4.9% | -4% | -2.94% |
3-Month Return | -8.01% | 0.84% | 3.53% |
6-Month Return | -9.76% | 12.62% | 22.95% |
1-Year Return | -21.15% | 7.99% | 26.43% |
3-Year Return | -49.4% | 18.97% | 26.19% |
5-Year Return | 520.54% | 71.39% | 86.42% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | 108.59M | 482.32M | 18.98B | 17.31B | 3.82B | [{"date":"2019-12-31","value":0.57,"profit":true},{"date":"2020-12-31","value":2.54,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":91.22,"profit":true},{"date":"2023-12-31","value":20.12,"profit":true}] |
Cost of Revenue | 243.83M | 704.36M | 3.86B | 4.53B | 599.80M | [{"date":"2019-12-31","value":5.38,"profit":true},{"date":"2020-12-31","value":15.54,"profit":true},{"date":"2021-12-31","value":85.19,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":13.23,"profit":true}] |
Gross Profit | (135.24M) | (222.04M) | 15.12B | 12.78B | 3.22B | [{"date":"2019-12-31","value":-0.89,"profit":false},{"date":"2020-12-31","value":-1.47,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":84.54,"profit":true},{"date":"2023-12-31","value":21.3,"profit":true}] |
Gross Margin | (124.54%) | (46.03%) | 79.66% | 73.82% | 84.29% | [{"date":"2019-12-31","value":-147.75,"profit":false},{"date":"2020-12-31","value":-54.61,"profit":false},{"date":"2021-12-31","value":94.5,"profit":true},{"date":"2022-12-31","value":87.57,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Expenses | 46.28M | (139.62M) | 200.10M | 135.90M | 2.31B | [{"date":"2019-12-31","value":2,"profit":true},{"date":"2020-12-31","value":-6.03,"profit":false},{"date":"2021-12-31","value":8.64,"profit":true},{"date":"2022-12-31","value":5.87,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (181.52M) | (82.42M) | 15.28B | 12.64B | 690.40M | [{"date":"2019-12-31","value":-1.19,"profit":false},{"date":"2020-12-31","value":-0.54,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":82.72,"profit":true},{"date":"2023-12-31","value":4.52,"profit":true}] |
Total Non-Operating Income/Expense | 1.81M | (66.87M) | (263.20M) | 622.80M | 281.90M | [{"date":"2019-12-31","value":0.29,"profit":true},{"date":"2020-12-31","value":-10.74,"profit":false},{"date":"2021-12-31","value":-42.26,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":45.26,"profit":true}] |
Pre-Tax Income | (179.44M) | (145.80M) | 15.05B | 12.95B | 1.19B | [{"date":"2019-12-31","value":-1.19,"profit":false},{"date":"2020-12-31","value":-0.97,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":86.09,"profit":true},{"date":"2023-12-31","value":7.88,"profit":true}] |
Income Taxes | (268.00K) | (161.00M) | 4.75B | 3.52B | 255.80M | [{"date":"2019-12-31","value":-0.01,"profit":false},{"date":"2020-12-31","value":-3.39,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":74.04,"profit":true},{"date":"2023-12-31","value":5.38,"profit":true}] |
Income After Taxes | (179.17M) | 15.20M | 10.29B | 9.43B | 930.30M | [{"date":"2019-12-31","value":-1.74,"profit":false},{"date":"2020-12-31","value":0.15,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":91.66,"profit":true},{"date":"2023-12-31","value":9.04,"profit":true}] |
Income From Continuous Operations | (179.17M) | 15.20M | 10.29B | 9.43B | 930.30M | [{"date":"2019-12-31","value":-1.74,"profit":false},{"date":"2020-12-31","value":0.15,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":91.66,"profit":true},{"date":"2023-12-31","value":9.04,"profit":true}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (179.17M) | 15.20M | 10.29B | 9.43B | 930.30M | [{"date":"2019-12-31","value":-1.74,"profit":false},{"date":"2020-12-31","value":0.15,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":91.66,"profit":true},{"date":"2023-12-31","value":9.04,"profit":true}] |
EPS (Diluted) | (0.39) | 0.07 | 39.69 | 36.93 | 3.83 | [{"date":"2019-12-31","value":-0.98,"profit":false},{"date":"2020-12-31","value":0.18,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":93.05,"profit":true},{"date":"2023-12-31","value":9.65,"profit":true}] |
These ratios help you determine the liquidity of the company. Higher is better.
BNTX | |
---|---|
Cash Ratio | 7.99 |
Current Ratio | 9.43 |
Quick Ratio | 9.26 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
BNTX | |
---|---|
ROA (LTM) | 2.62% |
ROE (LTM) | 4.62% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
BNTX | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.12 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.88 |
Debt/Equity The higher the number, the more leverage the business employs, the riskier the investment typically is. | 1.14 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
BNTX | |
---|---|
Trailing PE | 21.15 |
Forward PE | 7.04 |
P/S (TTM) | 5.46 |
P/B | 0.96 |
Price/FCF | 32 |
EV/R | 0.87 |
EV/Ebitda | 3.06 |
PEG | NM |
GlaxoSmithKline sued Pfizer and BioNTech in Delaware federal court on Thursday, accusing them of infringing GSK patents related to messenger RNA (mRNA) technology in the companies'' blockbuster COVID-19 vaccines.
Pfizer and BioNTech are locked in a legal dispute with vaccine maker Moderna at the High Court in London over the use of messenger RNA (mRNA) technology in coronavirus jabs.
Pfizer and BioNTech are locked in a legal dispute with vaccine maker Moderna at the High Court in London over the use of messenger RNA (mRNA) technology in coronavirus jabs.
Moderna, Pfizer and BioNTech are in a dispute over the rights to life-saving vaccine technology patents.
Pfizer and BioNTech asked a London court to revoke rival Moderna''s patents over technology key to the development of vaccines for COVID-19, as the latest leg of a global legal battle began on Tuesday.
The hearing is due to start at the High Court in London
Moderna claims that it is owed compensation for the infringement on its advanced mRNA technology.
BioNTech SE (Nasdaq: BNTX) will report its first-quarter 2024 financial results on May 6, 2024. The Company will host a conference call and webcast to discuss the results and provide a corporate update for investors, financial analysts, and the general public.
NIH Refuses To Release Details Of COVID-19 Vaccine Royalty Agreement Authored by Zachary Stieber via The Epoch Times (emphasis ours), The U.S. National Institutes of Health (NIH) is refusing to release additional information about an agreement it reached over a COVID-19 vaccine that has earned it at least $400 million. Syringes of Moderna COVID-19 vaccines at a vaccination site in Los Angeles, on Feb. 16, 2021. (Apu Gomes/AFP via Getty Images) The NIH declined to provide any materials in response to a Freedom of Information Act request from The Epoch Times. “ The NIH withholds the entirety of the records as they are protected from release ,” Gorka Garcia-Malene, an NIH officer, told The Epoch Times in a letter. She cited an exemption outlined in the act that allows government agencies to partially or fully withhold information. “In this case, exemption 3 incorporates 35 U.S.C. 209 (f), which reads in relevant part, ‘No Federal agency shall grant any license under a patent or patent application on a federally owned invention unless the person requesting the license has supplied the agency with a plan for development or marketing of the invention, except that any such plan shall be treated by the Federal agency as commercial and financial information obtained from a person and privileged and confidential and not subject to disclosure under section 552 of title 5,’” Ms.
BioNTech SE (BNTX) share price today is $87.21
Yes, Indians can buy shares of BioNTech SE (BNTX) on Vested. To buy BioNTech SE from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BNTX stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of BioNTech SE (BNTX) via the Vested app. You can start investing in BioNTech SE (BNTX) with a minimum investment of $1.
You can invest in shares of BioNTech SE (BNTX) via Vested in three simple steps:
The 52-week high price of BioNTech SE (BNTX) is $125.83. The 52-week low price of BioNTech SE (BNTX) is $85.21.
The price-to-earnings (P/E) ratio of BioNTech SE (BNTX) is 20.57
The price-to-book (P/B) ratio of BioNTech SE (BNTX) is 0.96
The dividend yield of BioNTech SE (BNTX) is 0.00%
The market capitalization of BioNTech SE (BNTX) is $20.73B
The stock symbol (or ticker) of BioNTech SE is BNTX